These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Yaswen L; Diehl N; Brennan MB; Hochgeschwender U Nat Med; 1999 Sep; 5(9):1066-70. PubMed ID: 10470087 [TBL] [Abstract][Full Text] [Related]
47. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies. Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151 [TBL] [Abstract][Full Text] [Related]
48. The central melanocortin system as a treatment target for obesity and diabetes: A brief overview. Goit RK; Taylor AW; Lo ACY Eur J Pharmacol; 2022 Jun; 924():174956. PubMed ID: 35430211 [TBL] [Abstract][Full Text] [Related]
49. Relationship of α-MSH and AgRP axons to the perikarya of melanocortin-4 receptor neurons. Lima LB; Pedroso JAB; Metzger M; Gautron L; Donato J Brain Res; 2019 Aug; 1717():136-146. PubMed ID: 31009611 [TBL] [Abstract][Full Text] [Related]
50. Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Mansour M; White D; Wernette C; Dennis J; Tao YX; Collins R; Parker L; Morrison E Endocrine; 2010 Feb; 37(1):220-30. PubMed ID: 20963574 [TBL] [Abstract][Full Text] [Related]
51. A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway. Kanti V; Puder L; Jahnke I; Krabusch PM; Kottner J; Vogt A; Richter C; Andruck A; Lechner L; Poitou C; Krude H; Gottesdiener K; Clément K; Farooqi IS; Wiegand S; Kühnen P; Blume-Peytavi U Skin Pharmacol Physiol; 2021; 34(6):307-316. PubMed ID: 34058738 [TBL] [Abstract][Full Text] [Related]
52. Signal pathway analysis of selected obesity-associated melanocortin-4 receptor class V mutants. Sharma S; Thibodeau S; Lytton J Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165835. PubMed ID: 32423884 [TBL] [Abstract][Full Text] [Related]
53. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. Lubrano-Berthelier C; Dubern B; Lacorte JM; Picard F; Shapiro A; Zhang S; Bertrais S; Hercberg S; Basdevant A; Clement K; Vaisse C J Clin Endocrinol Metab; 2006 May; 91(5):1811-8. PubMed ID: 16507637 [TBL] [Abstract][Full Text] [Related]
54. Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists. Molden BM; Cooney KA; West K; Van Der Ploeg LH; Baldini G Mol Endocrinol; 2015 Nov; 29(11):1619-33. PubMed ID: 26418335 [TBL] [Abstract][Full Text] [Related]
55. Molecular cloning, tissue distribution, and pharmacological characterization of melanocortin-4 receptor in spotted scat, Scatophagus argus. Li JT; Yang Z; Chen HP; Zhu CH; Deng SP; Li GL; Tao YX Gen Comp Endocrinol; 2016 May; 230-231():143-52. PubMed ID: 27080551 [TBL] [Abstract][Full Text] [Related]
56. Age-dependent hypothalamic expression of neuropeptides in wild-type and melanocortin-4 receptor-deficient mice. Arens J; Moar KM; Eiden S; Weide K; Schmidt I; Mercer JG; Simon E; Korf HW Physiol Genomics; 2003 Dec; 16(1):38-46. PubMed ID: 14559977 [TBL] [Abstract][Full Text] [Related]
57. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Fani L; Bak S; Delhanty P; van Rossum EF; van den Akker EL Int J Obes (Lond); 2014 Feb; 38(2):163-9. PubMed ID: 23774329 [TBL] [Abstract][Full Text] [Related]